![Steven Gannon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Steven Gannon
Direktor/Vorstandsmitglied bei
XENON PHARMACEUTICALS INC.
Vermögen: 649 645 $ am 31.05.2026
Profil
Steven Gannon is currently Director at enGene, Inc. since 2017, Independent Director at Xenon Pharmaceuticals, Inc. since 2015, and Director at Altasciences Co., Inc. since 2021.
Former roles include Director at 2941881 Canada, Inc., Director-Finance & Administration at AstraZeneca Canada, Inc. from 1996 to 1999, Director at Aerogen Ltd. from 2018 to 2020, Independent Non-Executive Director at Advanced Accelerator Applications SA from 2014 to 2018, Treasurer & Director at Multiple Myeloma Canada, Independent Director at Fusion Pharmaceuticals, Inc. from 2020 to 2024, Chief Financial Officer at CryoCath Technologies, Inc. from 1999 to 2006, Chief Financial Officer, Treasurer & Senior VP at Aptalis Pharma LLC from 2011 to 2014, Chief Financial Officer at Mallinckrodt Medical, Inc. from 1989 to 1995, and Chief Financial Officer, Treasurer & Senior VP at Aptalis Holdings, Inc. in 2008.
Education includes an undergraduate degree from Concordia University conferred in 1983.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 03.06.2026 | 11’870 ( 0.01% ) | 649 645 $ | 31.05.2026 |
Aktive Positionen von Steven Gannon
| Unternehmen | Position | Beginn |
|---|---|---|
| XENON PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 21.05.2015 |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which develops non-viral gene therapies | Direktor/Vorstandsmitglied | 01.02.2017 |
Altasciences Co., Inc.
 Altasciences Co., Inc. Miscellaneous Commercial ServicesCommercial Services Offers contract research organization and early-phase drug development & preclinical safety testing services | Direktor/Vorstandsmitglied | 01.04.2021 |
Ehemalige bekannte Positionen von Steven Gannon
| Unternehmen | Position | Ende |
|---|---|---|
| FUSN PHAR | Direktor/Vorstandsmitglied | 04.06.2024 |
Aerogen Ltd.
 Aerogen Ltd. Medical SpecialtiesHealth Technology Develops and manufactures aerosol products | Direktor/Vorstandsmitglied | 01.07.2020 |
| ADVANCED ACCELERATOR APPLICATION SA(ADR) | Direktor/Vorstandsmitglied | 01.03.2018 |
Aptalis Pharma LLC
 Aptalis Pharma LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures, markets pharmaceutical products for cystic fibrosis and gastroenterology | Finanzdirektor/CFO | 01.02.2014 |
CryoCath Technologies, Inc.
 CryoCath Technologies, Inc. Medical SpecialtiesHealth Technology Manufactures medical equipment | Finanzdirektor/CFO | 01.01.2006 |
Ausbildung von Steven Gannon
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
61
Beziehungen ersten Grades
14
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
CryoCath Technologies, Inc.
CryoCath Technologies, Inc. Medical SpecialtiesHealth Technology Manufactures medical equipment | Health Technology |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which develops non-viral gene therapies | Health Technology |
2941881 Canada, Inc.
 2941881 Canada, Inc. Medical SpecialtiesHealth Technology Manufactures and supplies medical equipment for the diagnosis and treatment of disorders in urology, gynecology, colorectal and gastrointestinal | Health Technology |
Aptalis Pharma LLC
Aptalis Pharma LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures, markets pharmaceutical products for cystic fibrosis and gastroenterology | Health Technology |
Mallinckrodt Medical, Inc.
 Mallinckrodt Medical, Inc. Medical SpecialtiesHealth Technology Manufactures and markets healthcare products | Health Technology |
Xenon Pharmaceuticals, Inc.
 Xenon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and delivering of therapeutics for neurological & psychiatric disorders | Health Technology |
Concordia University
 Concordia University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AstraZeneca Canada, Inc.
 AstraZeneca Canada, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drug preparations | Health Technology |
Aerogen Ltd.
Aerogen Ltd. Medical SpecialtiesHealth Technology Develops and manufactures aerosol products | Health Technology |
Advanced Accelerator Applications SA
 Advanced Accelerator Applications SA Pharmaceuticals: MajorHealth Technology Develops and produces nuclear medicine and radioligand therapies | Health Technology |
Aptalis Holdings, Inc.
 Aptalis Holdings, Inc. Pharmaceuticals: MajorHealth Technology Operating as a holding company that develops, manufactures, licenses, markets and distributes therapies | Health Technology |
Altasciences Co., Inc.
Altasciences Co., Inc. Miscellaneous Commercial ServicesCommercial Services Offers contract research organization and early-phase drug development & preclinical safety testing services | Commercial Services |
Multiple Myeloma Canada
 Multiple Myeloma Canada Miscellaneous Commercial ServicesCommercial Services Engages in clinical research which focuses on myeloma, a cancer of the plasma cells found in the bone marrow | Commercial Services |
Fusion Pharmaceuticals, Inc.
 Fusion Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals for the treatment of cancer | Health Technology |
